MENU CONTENTS

Biotechnology Research Institute

Aiming at No.1 Stem Cell Biotech Company,We Study the Future of Stem Cell Drugs

The human Umbilical Cord Blood-derived Mesenchymal Stem Cells (hUCB-MSCs) is recognized as a precious life resource
for secreting various therapeutic substances that treat incurable diseases by regenerating the damaged tissues.

Through investigation on the characteristics of human cord blood-derived stem cell,
MEDIPOST’s Biotechnology Research Institute is currently proceeding further researches on verification of the effect of cell therapeutic drugs; exploration on the therapeutic mechanisms and administration path;
and improvement of culture technique and productivity.

The institute has been applying for patents to obtain intellectual property rights for various research findings.
The results are also published in international academic journals, obtaining wide recognition for their research achievements.

Through innovations in treating incurable diseases with stem cell technologies, MEDIPOST Biotechnology Research Institute will improve the quality of human lives

External Collaboration Research

MEDIPOST
BRI

  • Verifying the
    Safety of the
    Stem Cell
  • Exploring the
    optimum for
    administration
  • Improving
    Productivity
  • Enhancing
    Therapeutic
    Effects
  • Verifying the
    effects on
    disease model
CARTISTEM®
  • KU Guro Hospital
  • GCU Gil Med Center
  • Samsung Med Center
  • Gangnam Severance
  • Asan Med Center
  • KBSMC
  • HYU Med Center
  • EWU Med Center
  • IHU Hospital
  • VHS Med Center
PNEUMOSTEM®
  • Pediatric Dept. at Samsung Med Center
  • Neonatology Dept. at Asan Med Center
NEUROSTEM®
  • Neurology Dept. / Neurosurgery Dept.
    at Samsung Med Center

상단으로